Recent Advances in Pyridine Scaffold: Focus on Chemistry, Synthesis, and Antibacterial Activities
Multidrug-resistant (MDR) pathogens have created a fatal problem for human health and antimicrobial treatment. Among the currently available antibiotics, many are inactive against MDR pathogens. In this context, heterocyclic compounds/drugs play a vital role. Thus, it is very much essential to explore new research to combat the issue. Of the available nitrogen-bearing heterocyclic compounds/drugs, pyridine derivatives are of special interest due to their solubility. Encouragingly, some of the newly synthesized pyridine compounds/drugs are found to inhibit multidrug-resistant S. aureus (MRSA). Pyridine scaffold bearing poor basicity generally improves water solubility in pharmaceutically potential molecules and has led to the discovery of numerous broad-spectrum therapeutic agents. Keeping these in mind, we have reviewed the chemistry, recent synthetic techniques, and bacterial preventative activity of pyridine derivatives since 2015. This will facilitate the development of pyridine-based novel antibiotic/drug design in the near future as a versatile scaffold with limited side effects for the next-generation therapeutics.
Top-30
Journals
|
1
2
3
4
5
6
7
8
|
|
|
Journal of Molecular Structure
8 publications, 9.09%
|
|
|
ChemistrySelect
4 publications, 4.55%
|
|
|
Journal of Organic Chemistry
3 publications, 3.41%
|
|
|
Molecules
3 publications, 3.41%
|
|
|
RSC Advances
3 publications, 3.41%
|
|
|
Organic Letters
2 publications, 2.27%
|
|
|
Journal of the Indian Chemical Society
2 publications, 2.27%
|
|
|
European Journal of Medicinal Chemistry Reports
2 publications, 2.27%
|
|
|
ChemCatChem
2 publications, 2.27%
|
|
|
Synthetic Communications
2 publications, 2.27%
|
|
|
Advanced Synthesis and Catalysis
2 publications, 2.27%
|
|
|
Russian Journal of Organic Chemistry
2 publications, 2.27%
|
|
|
Future Medicinal Chemistry
2 publications, 2.27%
|
|
|
Results in Chemistry
2 publications, 2.27%
|
|
|
Pharmaceuticals
1 publication, 1.14%
|
|
|
Animals
1 publication, 1.14%
|
|
|
Drugs and Drug Candidates
1 publication, 1.14%
|
|
|
Topics in Current Chemistry
1 publication, 1.14%
|
|
|
Journal of Industrial and Engineering Chemistry
1 publication, 1.14%
|
|
|
Molecular Diversity
1 publication, 1.14%
|
|
|
BMC Complementary Medicine and Therapies
1 publication, 1.14%
|
|
|
Expert Opinion on Drug Discovery
1 publication, 1.14%
|
|
|
MolBank
1 publication, 1.14%
|
|
|
Chemistry - A European Journal
1 publication, 1.14%
|
|
|
Pharmaceutics
1 publication, 1.14%
|
|
|
The Microbe
1 publication, 1.14%
|
|
|
Russian Journal of General Chemistry
1 publication, 1.14%
|
|
|
Organic and Biomolecular Chemistry
1 publication, 1.14%
|
|
|
Advanced Agrochem
1 publication, 1.14%
|
|
|
1
2
3
4
5
6
7
8
|
Publishers
|
5
10
15
20
25
|
|
|
Elsevier
21 publications, 23.86%
|
|
|
Wiley
15 publications, 17.05%
|
|
|
Springer Nature
14 publications, 15.91%
|
|
|
MDPI
11 publications, 12.5%
|
|
|
American Chemical Society (ACS)
7 publications, 7.95%
|
|
|
Taylor & Francis
6 publications, 6.82%
|
|
|
Royal Society of Chemistry (RSC)
5 publications, 5.68%
|
|
|
Pleiades Publishing
4 publications, 4.55%
|
|
|
Korean Society of Industrial Engineering Chemistry
1 publication, 1.14%
|
|
|
Asian Journal of Chemistry
1 publication, 1.14%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 1.14%
|
|
|
Center of Pharmaceutical Analytics Ltd
1 publication, 1.14%
|
|
|
5
10
15
20
25
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.